Hyperion DeFi (HYPD) Stock Overview
An ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HYPD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hyperion DeFi, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.58 |
| 52 Week High | US$17.18 |
| 52 Week Low | US$0.85 |
| Beta | 2.81 |
| 1 Month Change | -0.83% |
| 3 Month Change | -67.66% |
| 1 Year Change | -59.36% |
| 3 Year Change | -97.51% |
| 5 Year Change | -99.34% |
| Change since IPO | -99.55% |
Recent News & Updates
Shareholder Returns
| HYPD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.8% | -0.8% | -1.4% |
| 1Y | -59.4% | 25.7% | 14.6% |
Return vs Industry: HYPD underperformed the US Pharmaceuticals industry which returned 25.7% over the past year.
Return vs Market: HYPD underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| HYPD volatility | |
|---|---|
| HYPD Average Weekly Movement | 17.7% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: HYPD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HYPD's weekly volatility has decreased from 35% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 14 | Hyunsu Jung | hyperiondefi.com |
Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd.
Hyperion DeFi, Inc. Fundamentals Summary
| HYPD fundamental statistics | |
|---|---|
| Market cap | US$29.09m |
| Earnings (TTM) | -US$26.40m |
| Revenue (TTM) | US$345.32k |
Is HYPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYPD income statement (TTM) | |
|---|---|
| Revenue | US$345.32k |
| Cost of Revenue | US$3.10m |
| Gross Profit | -US$2.76m |
| Other Expenses | US$23.64m |
| Earnings | -US$26.40m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.23 |
| Gross Margin | -798.12% |
| Net Profit Margin | -7,643.89% |
| Debt/Equity Ratio | 10.8% |
How did HYPD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 23:43 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hyperion DeFi, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James McIlree | Chardan Capital Markets, LLC |
| Timothy Chiang | Northland Capital Markets |
| Esther Rajavelu | Oppenheimer & Co. Inc. |